NKTR 214

Drug Profile

NKTR 214

Alternative Names: BMS-986321; NKTR-214

Latest Information Update: 09 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nektar Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Developer Bristol-Myers Squibb; Nektar Therapeutics; Takeda; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytokines
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Sarcoma
  • Phase I/II Bladder cancer; Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Preclinical Lymphoma

Most Recent Events

  • 21 Sep 2018 Nektar Therapeutics and Vaccibody agree to co-develop VB10.NEO and NKTR 214 as combination therapy for Squamous cell cancer of the head and neck
  • 21 Sep 2018 Nektar Therapeutics and Vaccibody plan a pilot study of NKTR 214 (Combination therapy) for Squamous cell cancer of the head and neck
  • 14 Sep 2018 Phase-III clinical trials in Malignant melanoma (First-line therapy, Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, In adolescents, In adults, In children, In the elderly) in Australia, USA (IV) (NCT03635983)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top